ALK and non-small cell lung carcinoma: For calculating the overall incidence of grade 3–4 ILD events, a total of 1,236 NSCLC patients were included: the events of ILD was reported in 25 out of 1,236 NSCLC patients received ALK-TKIs with an incidence of 2.5% (95% CI: 1.7–3.6%, Figure 2A).